ALLIANCE PHARMA PLC

Major Shareholding Notification • Apr 28, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6809D

Alliance Pharma PLC

28 April 2017

For immediate release	28 April 2017

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Changes to interests of a significant shareholder

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder.   In accordance with AIM rule 17, the following details are now notified:

(a)  Identity of the significant shareholder: Aviva plc and its subsidiaries

(b)  Date of disclosure: 27 April 2017

(c)   Date of relevant change: 26 April 2017

(d)  Price, amount and class: 1,450,000 ordinary shares of 1p each; price not disclosed

(e)  Nature of transaction: sale of shares

(f)   Nature and extent of significant shareholder's interest: direct and indirect interests

(g)  Resultant shareholding: 4.69% (direct) and 0.16% (indirect)

In compliance with DTR5, a copy of the notification received from this investor is appended.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii			Alliance Pharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		Aviva plc & its subsidiaries
4. Full name of shareholder(s)  (if different from 3.):iv		Registered Holder: Available on request                                           18,450*                                                               Chase (GA Group) Nominees Limited       22,157,310* *denotes direct interest Chase Nominees Limited                                 733,516
5. Date of the transaction and date on which the threshold is crossed or reached: v		26 April 2017
6. Date on which issuer notified:		27 April 2017
7. Threshold(s) that is/are crossed or reached: vi, vii		5% to <5% Change at Combined Interest Level (Box 8A & Box  8A&B)

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction				Resulting situation after the triggering transaction
Number of Shares		Number of Voting Rights		Number of shares	Number of voting rights			% of  voting rights x
Direct	Direct xi		Indirect xii	Direct		Indirect
Ordinary Shares GB0031030819	24,359,276*		24,359,276*		22,909,276	22,175,760		733,516	4.69%		0.16%
* Includes Right to Recall Loaned Shares (50,000)
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Expiration date xiii		Exercise/ Conversion Period xiv			Number of voting rights that may be acquired if the instrument is exercised/ converted.			% of voting rights
RIGHT TO RECALL LOANED SHARES		N/A		N/A			50,000* *Direct Interest			0.01%

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx
					Nominal	Delta

Total (A+B+C)
Number of voting rights	Percentage of voting rights
22,959,276	4.86%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited and Friends Provident International Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited) Friends Provident International Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Friends Provident International Limited (wholly owned subsidiary of Aviva Group Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:		See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Figures are based on a total number of voting rights of  472,795,052, as per the Company's 'Application for admission' announcement of 31 March 2017.
14. Contact name:	Neil Whittaker, Aviva plc
15. Contact telephone number:	01603 684420

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLPGUBWCUPMURR